Emerson Electric
EMR
$0.00
-0.34%
Emerson Electric Co. is a leading global provider of industrial automation solutions, operating within the Industrial - Machinery sector. The company has strategically transformed itself into a pure-play automation player through divestitures of its climate technology and consumer businesses, focusing on automation software, power tools, and critical hardware like valves, gauges, and switches. The current investor narrative centers on the company's strategic pivot and its positioning to capitalize on the long-term secular trend of factory automation, which promises to enhance productivity and operational efficiency for manufacturers, a theme underscored by its recent segment realignment and financial results.…
EMR
Emerson Electric
$0.00
Investment Opinion: Should I buy EMR Today?
Rating & Thesis: Emerson Electric is rated a Hold. The core thesis is that while the company's strategic pivot to automation is compelling and fundamentals are solid, near-term growth deceleration and a full valuation create a balanced risk/reward profile, warranting patience for a better entry point or clearer signs of re-acceleration. This aligns with the neutral-to-cautious consensus reflected in analyst actions.
Supporting Evidence: The Hold rating is supported by four key data points. First, valuation is full at a forward P/E of 20.02x, a premium to typical industrials. Second, revenue growth decelerated sharply to 4.07% in Q1 from 16.3% in the prior quarter. Third, profitability remains strong with a 13.9% net margin and $2.575B in TTM FCF. Fourth, the implied analyst target upside of over 50% suggests long-term potential but requires growth expectations to be met.
Risks & Conditions: The two biggest risks are a prolonged growth slowdown below 5% and further gross margin compression below 48%. This Hold would upgrade to a Buy if the forward P/E compresses below 17x (offering a better margin of safety) or if quarterly revenue growth re-accelerates sustainably above 8% YoY. It would downgrade to a Sell if revenue growth turns negative or TTM FCF meaningfully deteriorates. Based on current data, the stock is considered fairly valued to slightly overvalued relative to its near-term growth trajectory, but retains long-term value if execution improves.
Sign up to view all
EMR 12-Month Price Forecast
Emerson presents a classic 'show me' story. The strategic rationale is sound, and the financial foundation is robust, but the stock's premium valuation demands proof that recent growth deceleration is temporary. The base case of steady, single-digit growth is most probable, leading to range-bound trading. The stance would upgrade to Bullish on concrete evidence of revenue re-acceleration (e.g., next quarter growth >7%) and stabilize margins. It would turn Bearish if growth stagnates or turns negative, triggering multiple compression. The high implied analyst upside offers a compelling long-term anchor, but near-term patience is advised.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
8 analysts
Implied Upside
—
vs. current price
Analyst Count
8
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst coverage for Emerson is moderate, with data from 8 analysts providing estimates. The consensus leans neutral to cautiously optimistic, as reflected in recent institutional actions which include a mix of 'Hold', 'Equal Weight', and 'Buy' ratings, with one notable downgrade from Deutsche Bank from 'Buy' to 'Hold' in early February. The average target price implied by the estimated EPS of $10.87 and a forward P/E of 20.02x is approximately $217.60, suggesting a significant implied upside of over 50% from the current price of $143.49, though this is a derived figure as explicit target prices are not provided in the data. The target range, inferred from estimated EPS, spans from a low of $10.67 to a high of $11.04, indicating a relatively tight spread and thus higher analyst conviction in the earnings outlook; the high end of the range would require multiple expansion or exceeding growth expectations, while the low end might factor in potential macroeconomic headwinds or margin pressures.
Bulls vs Bears: EMR Investment Factors
The investment debate for Emerson centers on the tension between its compelling strategic repositioning as a pure-play automation leader and the near-term financial metrics that show signs of strain. The bull case is anchored in strong profitability, cash flow, analyst conviction, and a clear secular tailwind. The bear case highlights decelerating revenue growth, premium valuation, and margin pressure. Currently, the bearish evidence holds slightly stronger weight due to the concrete slowdown in revenue growth from 16.3% to 4.1% and the premium valuation that demands flawless execution. The single most important factor is whether Q1's growth deceleration and margin compression are temporary or signal a more persistent slowdown that would invalidate the growth premium.
Bullish
- Strong Strategic Pivot to Pure-Play Automation: Emerson's divestiture of non-core businesses has successfully repositioned it as a focused automation player, capitalizing on the secular trend of factory digitalization. This strategic clarity is reflected in its segment performance, with Intelligent Devices generating $2.39B and Software and Systems $1.45B in Q1 2026, demonstrating the core growth engines are intact.
- Robust Profitability and Cash Generation: The company maintains healthy margins, with a Q1 2026 operating margin of 19.80% and a net margin of 13.9%. Critically, it generates substantial free cash flow, with TTM FCF of $2.575 billion, providing ample liquidity for dividends, buybacks, and strategic investments without straining the balance sheet.
- Analyst Consensus Implies Significant Upside: Based on the average estimated EPS of $10.87 and a forward P/E of 20.02x, the implied analyst target price is approximately $217.60. This represents a potential upside of over 50% from the current price of $143.49, indicating strong fundamental conviction in the company's earnings trajectory.
- Solid Balance Sheet with Manageable Leverage: Financial risk is low, with a debt-to-equity ratio of 0.678 and a return on equity of 11.31%. The strong cash flow profile further de-risks the capital structure, allowing Emerson to navigate economic cycles while funding its growth initiatives.
Bearish
- Revenue Growth Deceleration is a Concern: Q1 2026 revenue growth slowed sharply to 4.07% YoY, down from 16.3% YoY in the prior quarter (Q1 2025 vs. Q1 2024). This deceleration raises questions about the near-term growth trajectory of the refocused automation business amidst a potential economic slowdown.
- Premium Valuation Relative to Sector Peers: Emerson trades at a forward P/E of 20.02x and an EV/EBITDA of 17.78x, a premium to typical industrial machinery peers. This leaves the stock vulnerable to multiple compression if earnings growth fails to meet the high expectations embedded in the price.
- Recent Gross Margin Compression: The Q1 2026 gross margin of 48.56% is notably below the TTM gross margin of 52.84%. This quarter-over-quarter pressure could indicate rising input costs, pricing competition, or a less favorable sales mix, threatening overall profitability.
- Long-Term Underperformance vs. Market: Despite recent gains, the stock's 1-year relative strength is -11.03%, meaning it has significantly lagged the S&P 500's 19.14% gain. This underperformance reflects persistent investor skepticism or sector headwinds that may not be fully resolved.
EMR Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +8.11%, though it has significantly underperformed the broader market, as indicated by a relative strength of -11.03%. Currently trading at $143.49, the price sits approximately 37% above its 52-week low of $122.64 but 13% below its 52-week high of $165.15, positioning it in the upper-mid range of its yearly band, suggesting recovered momentum but not yet at overextended levels. Recent short-term momentum is positive but mixed, with a 1-month gain of +2.70% and a stronger 3-month gain of +14.43%, indicating accelerating momentum off a base; however, the stock's 1-month relative strength of +5.56% versus the SPY's -2.86% decline shows it is outperforming in the near term, potentially signaling a reversal of its longer-term underperformance. Key technical levels are clearly defined by the 52-week high at $165.15 as major resistance and the low at $122.64 as support; a breakout above resistance would confirm a new bullish phase, while a breakdown below support could signal a deeper correction. The stock's beta of 1.246 indicates it is approximately 25% more volatile than the market, which is relevant for risk-adjusted positioning, and the substantial 1-year max drawdown of -23.74% highlights the historical volatility investors have endured.
Beta
1.24
1.24x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$123-$165
Price range past year
Annual Return
+0.9%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | -2.1% | -1.3% |
| 3m | +5.6% | +13.6% |
| 6m | +2.4% | +9.0% |
| 1y | +0.9% | +19.1% |
| ytd | +2.4% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Revenue growth is positive but shows signs of deceleration; the most recent Q1 2026 revenue was $4.345 billion, representing a year-over-year growth of 4.07%, which is a slowdown from the 16.3% YoY growth seen in the prior Q4 (Q1 2025 vs. Q1 2024). Segment data reveals the Intelligent Devices segment contributed $2.39 billion, Software and Systems $1.453 billion, and Safety and Productivity $503 million, indicating the core automation businesses are driving the top line. The company is solidly profitable, with Q1 2026 net income of $605 million and a net margin of 13.9%; gross margin for the quarter was 48.56%, which is below the trailing twelve-month gross margin of 52.84%, suggesting some recent compression, though the operating margin of 19.80% remains healthy. Profitability has been consistent, with net income growing from $585 million in Q1 2025 to the current $605 million, and the TTM free cash flow of $2.575 billion supports strong cash generation. The balance sheet is in good health with a manageable debt-to-equity ratio of 0.678 and a current ratio of 0.876; the return on equity of 11.31% and return on assets of 6.68% reflect efficient use of capital, while the substantial TTM free cash flow of $2.575 billion provides ample internal funding for growth initiatives, dividends, and share repurchases, reducing financial risk.
Quarterly Revenue
$4.3B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.48%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Given the positive net income of $605 million in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is 32.23x, while the forward P/E is significantly lower at 20.02x; this substantial gap implies the market is pricing in robust earnings growth expectations for the coming year. Compared to sector averages, Emerson trades at a premium; its forward P/E of 20.02x is above typical industrial machinery averages (often in the mid-teens), and its Price/Sales ratio of 4.10x and EV/EBITDA of 17.78x also suggest a premium valuation, which may be justified by its pure-play automation focus and higher growth profile relative to traditional industrials. Historically, the current trailing P/E of 32.23x is near the top of its own range over recent quarters, which have fluctuated between approximately 15x and 97x, indicating the stock is pricing in relatively optimistic expectations, though not at extreme historical highs seen during periods of abnormally low earnings.
PE
32.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~98x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Emerson's primary financial risk is its premium valuation (forward P/E 20.02x) which necessitates sustained high growth to justify. The recent deceleration in revenue growth to 4.07% YoY and compression in gross margin from a TTM level of 52.84% to 48.56% in Q1 are concrete operational risks. If these trends persist, the company's earnings growth could disappoint, leading to significant multiple contraction. While the balance sheet is strong with a D/E of 0.678 and robust FCF, the company's valuation leaves little room for operational missteps.
Market & Competitive Risks: The stock faces clear valuation compression risk, as its forward P/E and EV/EBITDA of 17.78x trade at a premium to the broader industrial sector. Its beta of 1.246 indicates higher sensitivity to market downturns, and a sector rotation away from growth-oriented industrials could pressure the stock further. Competitive risks are inherent in the automation space, where Emerson must continually innovate in software and hardware to maintain its market position against both established rivals and new entrants. The recent analyst downgrade from Deutsche Bank to 'Hold' reflects emerging concerns about these external pressures.
Worst-Case Scenario: The worst-case scenario involves a combination of a broader economic downturn that curtails capital expenditure in automation, sustained gross margin pressure eroding profitability, and a failure to re-accelerate revenue growth. This could trigger a wave of analyst downgrades and a derating of the forward P/E towards the sector average (e.g., low-teens). In this adverse scenario, the stock could realistically revisit its 52-week low of $122.64, representing a downside of approximately -15% from the current price of $143.49. The historical max drawdown of -23.74% provides a benchmark for potential peak-to-trough loss in a severe bear case.
FAQ
The key risks are, in order of severity: 1) Growth Execution Risk: Revenue growth decelerated sharply to 4.07% YoY; a failure to re-accelerate would crush the growth premium. 2) Valuation Compression Risk: Trading at a forward P/E of 20.02x, the stock is vulnerable to derating if earnings disappoint. 3) Macroeconomic Risk: With a beta of 1.246, it is sensitive to economic cycles that could delay industrial automation spending. 4) Margin Pressure Risk: Q1 gross margin of 48.56% was below the TTM average of 52.84%, threatening profitability.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $165 and $185, assuming steady execution and a stable P/E multiple. The Bull Case (25% probability) targets $217 to $230, requiring a re-acceleration of growth and margin expansion. The Bear Case (15% probability) warns of a drop to $122-$140 if growth stalls and the multiple contracts. The base case is most likely, anchored by the current valuation and growth rate, with the stock's path heavily dependent on the next few quarterly earnings reports.
EMR appears fairly valued to slightly overvalued based on its near-term growth trajectory. Its forward P/E of 20.02x and EV/EBITDA of 17.78x command a premium to many industrial machinery peers, which typically trade at lower multiples. This premium is justified by its pure-play automation focus and strong cash generation, but it is contingent on the company delivering robust earnings growth. Given the recent slowdown to 4.07% revenue growth, the current valuation leaves little margin for error, implying the market is pricing in a successful re-acceleration.
EMR is a good buy for long-term investors comfortable with a 'show me' period and moderate volatility, but not for short-term traders seeking immediate momentum. The implied analyst target suggests over 50% upside, and the company's strong cash flow ($2.575B TTM FCF) and strategic focus are positives. However, the recent deceleration in revenue growth to 4.07% and a full forward P/E of 20.02x create near-term headwinds. It becomes a more compelling buy on a pullback toward $130 or upon clear evidence of growth re-acceleration in upcoming quarterly results.
EMR is primarily suitable for a long-term investment horizon of 3-5 years. Its strategic transformation into a pure-play automation company is a multi-year story that requires time to fully realize value and navigate cyclicality. The stock's beta of 1.246 and history of a -23.74% max drawdown make it less ideal for short-term trading, as volatility can be significant. The company's strong free cash flow supports a dividend, adding an income component for long-term holders. A minimum holding period of 18-24 months is suggested to allow the growth narrative to unfold.